Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Natera reports record-breaking Q3 earnings, poised for continued growth

Natera's Q3 2024 showcased exceptional financial performance, strong clinical advancements, and strategic debt management, positioning the company for sustained growth and innovation.
While facing challenges in community penetration and operational expenses, Natera's focus on innovation, customer service, and expanding clinical trials presents significant opportunities for future success.
With a clear focus on oncology patients, groundbreaking research, and upcoming data readouts, Natera remains poised for continued growth and leadership in the precision medicine space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera, Inc. is doubling down on its growth initiatives to expand its product portfolio beyond the non-invasive prenatal testing market. The company's growth initiatives highlight strategic discrepancies between the Texas-based molecular diagnostic company and its peers, with clearer profitability paths.

Natera's Worrisome Cash Burn

Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis AUSTIN, Texas , Dec. 9, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology highlighting the clinical utility of its personalized and tumor-informed molecular residual disease test, Signatera™, for postoperative risk stratification and prediction of recurrence in patients with stage I-III esophageal and gastric cancers (EGCs). The full study can be found here.

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

AUSTIN, Texas , Dec. 7, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Natera will present two posters from the LEADER and I-SPY 2 clinical trials in HR+, HER2- breast cancer highlighting Signatera's ability to detect recurrence and facilitate treatment response monitoring.

Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium

Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights unique capabilities of Panorama SNP-based NIPT AUSTIN, Texas , Dec. 6, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication in Prenatal Diagnosis of a clinical experience study in twin pregnancies featuring its Panorama single nucleotide polymorphism (SNP)-based noninvasive prenatal test (NIPT). These real-world results are consistent with previously reported performance of NIPT in twins, and reinforce the importance of Panorama's unique ability to determine zygosity and incorporate this information into risk assessments.

Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT

AUSTIN, Texas , Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m.

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

ctDNA reduction at week nine in patients treated with tebentafusp was associated with improved overall survival AUSTIN, Texas , Nov. 21, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows that its mPCR technology is able to assess response to tebentafusp in treatment-refractory metastatic uveal melanoma. The findings indicated an association between early reductions in ctDNA and longer overall survival, suggesting that traditional radiographic-based response criteria don't accurately reflect tebentafusp-related clinical activity and benefit.

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions.

Natera Announces Pricing of Follow-On Offering

Natera, Inc. (NASDAQ:NTRA ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Puneet Souda - SVB Securities Tejas Savant - Morgan Stanley Max Masucci - Cowen Julia Qin - JPMorgan Catherine Schulte - Baird Operator Welcome to Natera's 2022 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Natera, Inc. (NTRA) Q3 2022 Earnings Call Transcript

AUSTIN, Texas , Nov. 8, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022. Recent Strategic and Financial Highlights Generated total revenues of $210.6 million in the third quarter of 2022 compared to $158.1 million in the third quarter of 2021, an increase of 33.2%.

Natera Reports Third Quarter 2022 Financial Results

AUSTIN, Texas , Nov. 2, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective Sept. 15, 2022, with the U.S. Department of Veterans Affairs (VA) National Precision Oncology Program, to provide minimal residual disease (MRD) and monitoring services with the company's personalized and tumor-informed MRD test, Signatera™.

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs

AUSTIN, Texas , Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9 at 10:25 a.m. PT (1:25 p.m.

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference

AUSTIN, Texas , Nov. 1, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third quarter ended September 30, 2022, after the market closes on November 8, 2022. Natera will host a conference call and webcast at 1:30 p.m.

Natera to Report its Third Quarter 2022 Results on November 8th

Media reports of dramatic consequences of incorrect gene test interpretation and use combined with allegations of aggressive billing tactics drove the NTRA shares reeling. This negative publicity alienated investors who seem to miscalculate its impact on NTRA's revenue, opening an opportunity for contrarian traders as the company continues executing its growth strategy.

Natera: Cracks In The Bearish Trade

Multi-site study shows personalized ctDNA analysis is highly prognostic of recurrence-free survival and outperforms CA-125 in identifying patients at high risk of recurrence AUSTIN, Texas , Oct. 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a manuscript in Gynecologic Oncology, found here , validating the performance of its personalized molecular residual disease (MRD) test, Signatera, in epithelial ovarian cancer (EOC). This study adds to the growing library of over 30 published clinical studies incorporating Signatera technology.

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer

AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta study in Transplantation, found here .  The investigators found that in predicting antibody mediated rejection (AMR), donor-derived cell-free DNA (dd-cfDNA) testing with the Prospera Kidney test was superior to the current standard of care, donor-specific antibody (DSA) testing.

Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

AUSTIN, Texas , Sept. 29, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity and improved access to health care.

Natera Announces 2025 ESG Goals with Publication of 2021 Report

Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN, Texas , Sept. 12, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

AUSTIN, Texas , Aug. 25, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at Natera in an independently administered, anonymous survey.

Natera Earns Great Place to Work Certification™ for Second Consecutive Year

RenaCARE Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease AUSTIN, Texas , Aug. 11, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight™ genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis.

Natera Announces Enrollment Completion for RenaCARE Study

AUSTIN, Texas , Aug. 10, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.

Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT

Natera, Inc. (NASDAQ:NTRA ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Tejas Savant - Morgan Stanley Dave Delahunt - Goldman Sachs Catherine Schulte - Baird Max Masucci - Cowen Puneet Souda - Leerink Julia Qin - JPMorgan Vidyun Bais - BTIG Connor Stevenson - Craig-Hallum Mason Carrico - Stephens Operator Welcome to Natera's 2022 Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Natera, Inc. (NTRA) CEO Steve Chapman on Q2 2022 Results - Earnings Call Transcript

AUSTIN, Texas , Aug. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights Generated total revenues of $198.2 million in the second quarter of 2022 compared to $142.0 million in the second quarter of 2021, an increase of 39.6%.

Natera Reports Second Quarter 2022 Financial Results

The consensus price target hints at a 47.5% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 47% Upside in Natera (NTRA): Here's What You Should Know

Wilmington, Delaware--(Newsfile Corp. - August 2, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Natera, Inc. (NASDAQ: NTRA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-natera-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Natera, Inc.

AUSTIN, Texas , Aug. 1, 2022 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2022, after the market close on August 4, 2022. Natera will host a conference call and webcast at 1:30 p.m.

News for Natera Stock (NTRA)